Kaleido Biosciences, Inc.
0.0M
$0.00M
-1.11
$-2.16
No price alerts set. Add an alert to get notified!
-1.11
9.43
$-2.16
-851.21%
-8,178.26%
-7,940.85%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ARNI
Arno Therapeutics, Inc.
|
$0.00 | 0.00 | 0.00 | $9,870 | -0.24 |
|
BTTX
Better Therapeutics, Inc.
|
$0.00 | 0.00 | 0.00 | $5,452 | -16.55 |
|
BXRXQ
Baudax Bio, Inc.
|
$0.00 | 900.00% | 0.00 | $4,359 | -0.29 |
|
CALA
Calithera Biosciences, Inc.
|
$0.00 | 200.00% | 0.00 | $1,462 | 0.08 |
|
IVBT
Innovation1 Biotech Inc.
|
$0.00 | 0.00 | 0.00 | $4,494 | -0.07 |
|
SNNAQ
Sienna Biopharmaceuticals, Inc.
|
$0.00 | 0.00 | 0.00 | $3,091 | 0.19 |
|
TLOG
TetraLogic Pharmaceuticals Corporation
|
$0.00 | 0.00 | 0.00 | $2,447 | -4.76 |
|
TNGNQ
Tengion, Inc.
|
$0.00 | 0.00 | 0.00 | $4,025 | -1.60 |
|
VIVE
Viveve Medical, Inc.
|
$0.00 | 0.00 | 0.00 | $2,145 | 0.36 |
|
XENO
Xeno Transplants Corporation
|
$0.00 | 0.00 | -0.03 | $4,036 | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$0.19
$0.00
$0.00
0.00%
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
